1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on July 1, 2025

GILD

Investing.com

13 hours ago

Gilead extends gains after Supreme Court upheld an Obamacare provision

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
GILD

Insider Monkey

3 days ago

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
GILD

Zacks

3 days ago

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care
GILD

Investor's Business Daily

3 days ago

Gilead, Exact Jump After The Supreme Court Upholds A 'Cornerstone' Of Health Care

GILD

Investing.com

3 days ago

Kymera’s partnerships with Sanofi and Gilead drive value

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Zacks

3 days ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
GILD

PR Newswire

3 days ago

Debut Named to TIME's List of the TIME100 Most Influential Companies 2025

Northwell Health named to TIME100 Most Influential Companies 2025 list
GILD

Business Wire

4 days ago

Northwell Health named to TIME100 Most Influential Companies 2025 list

Kymera weakness a buying opportunity, says Stifel
GILD

TipRanks

4 days ago

Kymera weakness a buying opportunity, says Stifel

Morning Movers: General Mills dips following fourth quarter report
GILD

TipRanks

4 days ago

Morning Movers: General Mills dips following fourth quarter report

Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know
GILD

Zacks

5 days ago

Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know

Alger Russell Innovation Index Updates for Second Quarter 2025
GILD

PR Newswire

5 days ago

Alger Russell Innovation Index Updates for Second Quarter 2025

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal
GILD

Simply Wall St.

5 days ago

Gilead Sciences (NasdaqGS:GILD) Partners With Kymera In US$750 Million Cancer Treatment Deal

FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP
GILD

Clinical Trials Arena

5 days ago

FDA approves Gilead’s twice-yearly injectable Yeztugo for PrEP

GILD

MT Newswires

5 days ago

Assembly Biosciences Says ABI-4334 Phase 1b Trial Showed 'Strong' Antiviral Activity in Chronic Hepatitis B

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
GILD

BioPharma Dive

6 days ago

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
GILD

GlobeNewswire

6 days ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

GILD

MT Newswires

6 days ago

Gilead Sciences, Kymera Therapeutics to Collaborate on Cancer Program

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
GILD

Business Wire

6 days ago

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion
GILD

ACCESS Newswire

6 days ago

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
GILD

Zacks

7 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call
GILD

StockStory

8 days ago

5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call

The FDA Shake-Up Continues, And Could Impact Genetic Medicines
GILD

Investor's Business Daily

10 days ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

BMO says lenacapavir approval for prevention a ‘major win’ for Gilead
GILD

TipRanks

11 days ago

BMO says lenacapavir approval for prevention a ‘major win’ for Gilead

GILD

MT Newswires

11 days ago

Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
GILD

Zacks

11 days ago

FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
GILD

Simply Wall St.

11 days ago

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
GILD

Zacks

11 days ago

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
GILD

Pharmaceutical Technology

12 days ago

Gilead Sciences’ Yeztugo receives approval from US FDA for HIV

Celltrion opens new UK headquarters in Uxbridge, UK
GILD

Business Wire

12 days ago

Celltrion opens new UK headquarters in Uxbridge, UK

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern
GILD

Insider Monkey

14 days ago

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
GILD

Insider Monkey

16 days ago

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
GILD

Zacks

18 days ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

GILD

MT Newswires

19 days ago

Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says

Citi sees Gilead clinical holds as only ‘minor setback’
GILD

TipRanks

19 days ago

Citi sees Gilead clinical holds as only ‘minor setback’

Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital
GILD

TipRanks

19 days ago

Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
GILD

TipRanks

19 days ago

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD

Zacks

19 days ago

FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?
GILD

Zacks

19 days ago

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

GILD

Argus Research

20 days ago

Technical Assessment: Bullish in the Intermediate-Term

GILD

MT Newswires

20 days ago

RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating

1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
GILD

StockStory

20 days ago

1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar

Why Gilead Scinces Stock Tumbled on Tuesday
GILD

Motley Fool

20 days ago

Why Gilead Scinces Stock Tumbled on Tuesday

GILD

MT Newswires

20 days ago

Gilead Says FDA Puts Clinical Hold on HIV Combination Trials

GILD

Investing.com

20 days ago

Gilead Sciences shares hit after HIV studies placed on hold by FDA

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
GILD

Zacks

24 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

2 Reasons to Like GILD (and 1 Not So Much)
GILD

StockStory

25 days ago

2 Reasons to Like GILD (and 1 Not So Much)

Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
GILD

ACCESS Newswire

25 days ago

Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"

A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech
GILD

The Wall Street Journal

a month ago

A New Shot Prevents HIV—and Breathes New Life Into a Stagnant Biotech

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
GILD

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

GILD

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $1,104,193, According to a Recent SEC Filing

1 Healthcare Stock Worth Your Attention and 2 to Turn Down
GILD

StockStory

a month ago

1 Healthcare Stock Worth Your Attention and 2 to Turn Down

Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
GILD

Zacks

a month ago

Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study

GILD

MT Newswires

a month ago

DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
GILD

Business Wire

a month ago

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
GILD

Reuters

a month ago

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
GILD

Business Wire

a month ago

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
GILD

Zacks

a month ago

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
GILD

ACCESS Newswire

a month ago

Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
GILD

Zacks

a month ago

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
GILD

Zacks

a month ago

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
GILD

Zacks

a month ago

GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer

Gilead’s Phase III trial for breast cancer therapy meets primary goal
GILD

Clinical Trials Arena

a month ago

Gilead’s Phase III trial for breast cancer therapy meets primary goal

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump
GILD

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump

Gilead announces ASCENT-03 study meets primary endpoint
GILD

TipRanks

a month ago

Gilead announces ASCENT-03 study meets primary endpoint

GILD

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $3,010,564, According to a Recent SEC Filing

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer
GILD

Simply Wall St.

a month ago

Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer

Gilead (GILD) to Acquire HOOK for $10 million
GILD

Insider Monkey

a month ago

Gilead (GILD) to Acquire HOOK for $10 million

GILD

MT Newswires

a month ago

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
GILD

Business Wire

a month ago

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

GILD

MT Newswires

a month ago

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise

Here's Why Gilead Sciences (GILD) is a Strong Value Stock
GILD

Zacks

a month ago

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
GILD

Zacks

a month ago

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

GILD

Argus Research

a month ago

Technical Assessment: Bullish in the Intermediate-Term

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA
GILD

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
GILD

Business Wire

2 months ago

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories
GILD

ACCESS Newswire

2 months ago

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
GILD

Zacks

2 months ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
GILD

Insider Monkey

2 months ago

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
GILD

StockStory

2 months ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

Trump expected to sign order to slash US drug prices
GILD

Yahoo Finance Video

2 months ago

Trump expected to sign order to slash US drug prices

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple
GILD

Zacks

2 months ago

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

US-China trade truce, April CPI, drug prices: 3 Things
GILD

Yahoo Finance Video

2 months ago

US-China trade truce, April CPI, drug prices: 3 Things

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
GILD

StockStory

2 months ago

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?
GILD

Insider Monkey

2 months ago

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

2 High-Yield Dividend Stocks to Buy in May and Hold Forever
GILD

Motley Fool

2 months ago

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton
GILD

Zacks

2 months ago

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

3 Value Stocks with Mounting Challenges
GILD

StockStory

2 months ago

3 Value Stocks with Mounting Challenges

Gilead reports final outcomes from trial of bulevirtide for chronic HDV
GILD

Clinical Trials Arena

2 months ago

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock
GILD

Benzinga

2 months ago

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead to Invest $11 Billion to Bolster Domestic Operations
GILD

The Wall Street Journal

2 months ago

Gilead to Invest $11 Billion to Bolster Domestic Operations

GILD

Investing.com

2 months ago

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead boosts planned US investments by $11 billion amid tariff threat
GILD

Reuters

2 months ago

Gilead boosts planned US investments by $11 billion amid tariff threat

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025
GILD

Simply Wall St.

2 months ago

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
GILD

Business Wire

2 months ago

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
GILD

Business Wire

2 months ago

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
GILD

ACCESS Newswire

2 months ago

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

GILD

MT Newswires

2 months ago

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
GILD

Zacks

2 months ago

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

GILD

Argus Research

2 months ago

Analyst Report: Gilead Sciences, Inc.

Share on Social Networks: